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Abstract
Background: Distant recurrences after antineoplastic treatment remain a serious problem for breast cancer clinical
management, which threats patients’ life. Systemic therapy is administered to eradicate cancer cells from the organism,
both at the site of the primary tumor and at any other potential location. Despite this intervention, a significant proportion
of breast cancer patients relapse even many years after their primary tumor has been successfully treated according to
current clinical standards, evidencing the existence of a chemoresistant cell subpopulation originating from the primary
tumor.
Methods/Findings: To identify key molecules and signaling pathways which drive breast cancer chemoresistance we
performed gene expression analysis before and after anthracycline and taxane-based chemotherapy and compared the
results between different histopathological response groups (good-, mid- and bad-response), established according to the
Miller & Payne grading system. Two cohorts of 33 and 73 breast cancer patients receiving neoadjuvant chemotherapy were
recruited for whole-genome expression analysis and validation assay, respectively. Identified genes were subjected to a
bioinformatic analysis in order to ascertain the molecular function of the proteins they encode and the signaling in which
they participate. High throughput technologies identified 65 gene sequences which were over-expressed in all groups (P #
0?05 Bonferroni test). Notably we found that, after chemotherapy, a significant proportion of these genes were over-
expressed in the good responders group, making their tumors indistinguishable from those of the bad responders in their
expression profile (P # 0.05 Benjamini-Hochgerg̀s method).
Conclusions: These data identify a set of key molecular pathways selectively up-regulated in post-chemotherapy cancer
cells, which may become appropriate targets for the development of future directed therapies against breast cancer.
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Introduction
The searching for predictive tumor biomarkers in breast cancer
treatment has been a major research issue for decades [1,2].
Indeed, the scientific community is conscious that a better and
more accurate system to identify individuals at increased risk of
recurrence, avoid under- and over-treatment and improve the
long-term survival rates of the patients, is needed [3,4]. In this
regard, the revolutionary scientific and technological advances in
the field of genomics has allowed the development of multi-gene
assays which have been approved and commercialized to guide
clinical decisions according with the particular characteristics of
tumors [5-9]. Despite substantial advances in this field, around
30% of patients with early-stage breast cancer relapse after an
unpredictable period, even if they achieved a good response to
systemic treatment [3,5]. This and other scientific findings, such as
the detection of circulating tumor cells (CTCs) in the bloodstream
of treated patients, has pointed out tumor chemoresistance as a
leading process involved in breast cancer progression [10,11].
Clearly, to be able to overcome cancer chemoresistance we
must first acquire a complete understanding of the molecular
processes and leading alterations which make possible this effect.
In this regard, a novel hypothesis involving dedifferentiated cells
with stem-like properties has been highlighted. The cancer stem
cell (CSC) hypothesis assumes that some neoplasms, such as breast
cancer, are the consequence of the accumulation of transforming
genetic and epigenetic changes in adult stem cells or their
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progressively differentiated progenitors. First experimental evi-
dence was reported by Al-Hajj et al. [12] who showed that the
transplantation of few cells characterized by the CD44+/CD24-
inmunophenotype in non-obese diabetic/severe combined immu-
nodeficient (NOD/SCID) immunocompromised mice formed
tumors that recapitulated the phenotypic heterogeneity of the
original breast tumors from which they were derived. Since then,
many studies have focused on the study of this putative tumor-
initiating cell population [13]. Remarkably, CSCs have been
related to chemoresistance since they present a low proliferation
rate, over-express cell surface proteins involved in drug efflux and
dug-metabolizing enzymes [14]. It has also been reported that
CSCs exert a radio-resistant behavior through the over-expression
of free radical scavenging systems [15]. Nevertheless, key
molecular processes conferring the ability to overcome drug-
induced toxicity and promote cancer cell survival in order to
establish a new oncogenic lesion, even several years after successful
systemic treatment, remains to be elucidated despite an increasing
amount of data regarding this issue is published yearly.
In relation to this issue, important concepts has been introduced
changing the way that scientist approach to the study of
chemoresistance and other oncologic events. From the works of
Greenman et al. [16] and Sjøblom et al. [17] it can be extracted
that tumors arise from the alteration of key genes known as ‘‘diver
mutations’’ which also direct tumor biology. The rest of genes
reported to be mutated at a lower frequency across different tumor
samples were termed ‘‘passenger mutations’’, which are thought to
be a consequence of tumor genomic instability but have a modest
impact on tumor phenotype. Indeed, it has been suggested that the
occurrence of passenger mutations and associated gene over- and
under-expression may be on the base of confounding results from
genomic studies, which may have identified different tumoral/
clinical entities under the same genomic category according to the
differential expression of genes that are transiently modified due to
the highly genomic instability to which are subjected tumor cells
[1]. Genes affected by driver mutations, the molecular processes
they direct and the signaling pathways in which they participate
are of great scientific interest given their therapeutic potential.
To investigate the biological processes which drive chemoresis-
tance in breast cancer, we designed and performed a gene
expression study which included patients who registered all
possible pathologic responses to this treatment. The comparison
of gene expression differences induced by chemotherapy allowed
the identification of 30 genes which were over-expressed after
chemotherapy regardless patient’s response to treatment.
Methods
Ethics statement
This study was approved by the local Ethical Review Board,
Comité de Ética de la Investigación de Jaén, and in accordance
with Good Clinical Practices and the tenets of the Declaration of
Helsinki. Patients provided their written informed consent to
participate in this study.
Patient population
This study included two independent sets of patients involving a
total of 118 breast cancer cases. All patients were staged based on
physical examination, radiologic findings and pathologic exami-
nation of tumor biopsies. Initially, we recruited 46 patients with a
histologically confirmed diagnosis of breast cancer and scheduled
neoadjuvant chemotherapy treatment based on Anthracyclines
and Taxanes, as determined by the medical oncology team. From
this cohort, 33 patients met the inclusion criteria for genome-wide
expression analysis with oligonucleotide microarrays. Nevertheless,
gene expression data from 4 pre-chemotherapy samples and 1
post-chemotherapy sample were discarded from final analysis as
microarrays data quality control identified them as outliers.
Consequently, whole genome gene expression analysis finally
included 56 matched pre- and post-chemotherapy samples from
28 cases plus 4 pre-chemotherapy and 1 post-chemotherapy
samples from 5 additional cases. Globally, 33 cases and 61 samples
were processed for whole genome expression analysis. To validate
the results derived from gene expression analysis, a qRT-PCR
assay was designed and formalin fixed paraffin embedded (FFPE)
tumor samples from 85 selected breast cancer cases who received
equivalent neoadjuvant chemotherapy were processed. Despite 85
patients were initially included in this validation experiment, a
final sample size of 73 cases were selected for data analysis due to
either of the following reasons: the patient refused chemotherapy,
the medical oncologist finally decided to change the treatment
scheduled, the patient experienced acute toxicity and did not finish
the treatment. The pathologic and clinical information from each
patient was extracted from the medical reports achieved in the
Oncology Department Registry.
Tumor tissue samples
Tumor samples from each patient included in this study
(Table 1) were obtained before and after chemotherapy. Pre-
chemotherapy tumor samples from the initial cohort were
obtained during diagnosis through ultrasound-guided core
needle biopsy and post-chemotherapy tumor samples were
obtained from surgery pieces after mastectomy or surgical
resection. Two core needle biopsies were obtained from each
of the cases included, one was flash frozen in liquid nitrogen
and stored at -80uC and the other was fixed in buffered
formalin and embedded in paraffin for standard histological
and immunohistochemical analyses. The same procedure was
followed to process and store the post-chemotherapy tumor
samples. Pre- and post-chemotherapy tumor samples were
frozen within 30 min after biopsy or surgery. Notably, this
assay was not biased for individual genetic differences, as most
samples used corresponded to paired pre- and post-treatment
samples from each case. Breast cancer patients were distrib-
uted in experimental groups according to their pathological
responses to anthraclycline and taxane-based chemotherapy,
as determined by the Miller and Payne grading system [18].
This resulted in a group of good responders -GR (Miller &
Payne grades 4 and 5)-, a group of mid response –MR (Miller
& Payne grade 3)- and a group of bad responders -BR (Miller
& Payne grades 1 and 2)-. For whole-genome expression
analysis cases were selected irrespectively of their Human
Epidermal growth factor Receptor 2 (Her2) status, unless it was
registered as a phenotypic tumor characteristic. Validation
experiment was performed in an independent set of 170 paired
formalin fixed paraffin embedded (FFPE) samples (before and
after chemotherapy) corresponding to 85 breast cancer cases.
The validation cohort comprised all pathological response
groups described and an extra group of patients with Human
Epidermal growth factor Receptor 2 (Her2) positive tumors
(Her2G). Her2-positive tumors are very different entities from
the molecular point of view [19]. On the other hand, the
addition of Trastuzumab, a therapeutic monoclonal antibody
against Her2, to anthraclycline and taxane-based chemother-
apy is routinely scheduled for these patients as it greatly
improves their pathological response to treatment [20]. Then,
the molecular and clinical distinctive characteristics of Her2-
positive tumors were the main arguments to include this extra
Genetic Drivers of Breast Cancer Chemoresistance
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group in our experimental design. Additionally, the MR group
was further subdivided into two groups for validation analysis –
mid-response high (MRH) and mid-response low (MRL)-. As in
the case of whole genome expression assay and for the same
reasons, this study was not biased for individual genetic
differences among cases (see Supporting Methods (Text S1)
and Figure S1 for a detailed explanation of the procedures
followed for tumor tissue selection).
Table 1. Population demographics and pre-chemotherapy clinical characteristics.
Whole-genome expression analysis cohort Validation assay cohort
Age at diagnosis in years
, 40 5 (15.1) 10 (13.7)
40-49 9 (27.3) 30 (41.1)
50-59 10 (30.3) 11 (15.1)




Ductal 30 (90.9) 65 (89.1)
Lobular 3 (3.1) 6 (8.2)
Mixed 0 (0) 2 (2.7)
T staging
T1 0 (0) 2 (2.7)
T2 28 (84.9) 48 (65.8)
T3 4 (12.1) 18 (24.7)
T4 1 (3) 5 (6.8)
N staging
N0 9 (27.3) 38 (52.1)
N1-3 24 (72.7) 35 (47.9)
AJCC Staging
IA/IB 0 (0) 1 (1.4)
IIA/IIB 18 (54.5) 56 (76.7)
IIIA/IIIB/IIIC 15 (45.5) 16 (21.9)
Bloom-Richardson’s histological grade
I 3 (9.1) 22 (30.1)
II 14 (42.4) 28 (38.4)
III 16 (48.5) 23 (31.5)
Estrogen receptor
+ 24 (72.7) 55 (75.3)
- 9 (27.3) 18 (26.7)
Progesterone receptor
+ 24 (72.7) 42 (57.5)
- 9 (27.3) 31 (42.5)
Her2
+ 6 (18.2) 15 (20.5)
- 27 (81.8) 58 (79.5)
Miller & Payne grade
1 and 2 (BR) 15 (45.4) 12 (20.7)
3 (MR) 9 (27.3) NA
3 – MRL (30-60% tumor cell reduction)- NA 12 (20.7)
3 – MRH (61-90% tumor cell reduction)- NA 15 (25.8)
4 and 5 (GR) 9 (27.3) 19 (32.8)
Results are presented as n (%) of 33 patients for the whole-genome expression analysis cohort and as n (%) of 73 patients for the validation assay cohort.
Abbreviations: AJCC, American Joint Committee on Cancer; BR, bad response group; GR, good response group; Her2G, Her2-positive group; MRH, mid-response high
group; MRL, mid-response low group; NA, not applicable.
doi:10.1371/journal.pone.0053983.t001.
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RNA isolation and microarray analysis
Sample processing, microarray hybridization and gene expres-
sion analysis were carried out with the Affymetrix Genechip
System (Affymetrix, Santa Clara, CA, USA). Briefly, total RNA
was extracted and purified for microarray analysis using
QIAshredder columns and the RNeasy Mini kit (Qiagen, Hilden,
Germany) according to manufacturer’s instructions. From 1mg of
total RNA, complementary DNA (cDNA) was synthesized using
the One-Cycle cDNA Synthesis kit (Affymetrix). Biotinylated
complementary RNA (cRNA) was synthesized following the IVT
labeling kit (Affymetrix) and purified using the GeneChip Sample
Cleanup Module (Affymetrix). Subsequently, Biotinylated cRNA
was fragmented and hybridized to the Genechip Human Genome
U133 Plus 2.0 microarrays (Affymetrix). After hybridization,
microarrays followed washing and staining protocol and were
scanned using the GeneChip Scanner 3000 (Affymetrix). The
fluorescent signal corresponding to the intensity of hybridization
intensity of each transcript was determined using the Gene Chip
Operating Software (GCOS 1.4; Affymetrix). Intensity values were
scaled such that the overall fluorescence intensity of each array was
equivalent. Finally, probe set measurements were generated from
quantified Affymetrix image (.CEL) files using the Robust
Multichip Average method (RMA) from the Affy package
Bioconductor (available at http://www.bioconductor.org).
Bonferroni test was estimated to correct for multiple tests,
considering P # 0.05 to be significant, and Fold-change (FC)
values were calculated for all comparisons. After non-supervised
Principal components analysis (PCA) and clustering, gene expres-
sion statistical significances were identified by two linear regression
models taking into account the pathologic response to chemo-
therapy, if the sample was obtained before or after systemic
treatment and the matching of pre- and post-chemotherapy
samples derived from the same patient. Supervised PCA analysis
and clustering were performed with processed data. Partek
Genomics Suite v7.3.1 (Partek, St. Louise, MO, USA) software
was employed for the statistic analysis and clustering and the
Euclidean distance for similarity measurements, and average
linkage was selected as association. Functional enrichment analysis
was carried out using the Protein ANalysis THrough Evolutionary
Relationships (PANTHER) (http://www.pantherdb.org) and the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) (http://david.abcc.ncifcrf.gov/) software.
Figure 1. Experimental design and main results from genome-wide expression analysis. A) Experimental design of the discovery assay. B)
Genes differentially over-expressed after chemotherapy C) Gene Ontology (GO) terms over-represented by the genes differentially over-expressed
after chemotherapy at a significance level of P,0.05. Circular representation must be read clockwise and legend must be read from left to right and
top to bottom. Numbers within the figure correspond to the number of genes classified in each GO category.
doi:10.1371/journal.pone.0053983.g001
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Quantitative real-time RT-PCR analysis
Based on the microarray results, expression levels of 90 genes were
evaluated using qPCR analysis. With this purpose, 5 sections of 10 mm
from each formalin-fixed, paraffin-embedded breast cancer sample
were processed to isolate 10 ng of total RNA using the RNesay FFPE
Kit (Qiagen). cDNAs were reverse-transcribed from total RNA
samples using the High Capacity cDNA Archive Kit (Applied
Biosystems) according to manufacturer’s instructions. TaqMan PCR
reactions were performed on cDNA samples using the Taqman Gene
Expression Master Mix (Applied Biosystems) in conjunction with
custom 7,900 microfluidic cards (Applied Biosystems) and ABI PRISM
7,900 HT Sequence Detection Systems, according to manufacturer’s
instructions. The gene set contained 6 housekeeping genes, GADPH,
HPRT1, MRPL19, RPLP0, TBP and TFRC selected according to
specific bibliography [21]. According to Genorm calculations, we
considered all six housekeeping genes for normalization. Absolute
threshold cycle values (Ct values) were determined by using SDS 2.2.2
software (Applied Biosystems).
DCt values were used as dependent variables in the statistical
analysis. A linear regression model (Limma) was used to detect
differentially expressed changes among groups and Benjamini and
Hochberg’s method was used to control the false discovery rate (FDR)
with an adjusted P-value threshold of 0.05.
Functional networks and pathways analyses were generated through
the use of Ingenuity Pathways Analysis (IPA) (Ingenuity SystemsH,
www.ingenuity.com). Fischer‘s exact test was used to calculate a P-
value determining the probability that each biological function and/or
disease assigned to that dataset and network is due to chance alone (P-
values # 0.05 were considered as significant). Activation z-score was
calculated as a measure of functional and translational activation in
Networks and Upstream regulators analysis. An absolute z-score of
below (inhibited) or above (activated) 2 was considered as significant
(see Supporting Methods (Text S1) for details).
Results
After comparing pre-chemotherapy and post-chemotherapy
samples, we identified a subset of 65 gene sequences whose
Figure 2. Main results from Post-CT vs Pre-CT comparisons in the validation assay. A) Log10 fold change in mRNA abundance of each
differentially expressed gene after chemotherapy considering all experimental groups together (Post-CT vs Pre-CT) and each experimental group
individually –GR (Post-CT vs Pre-CT), Her2G (Post-CT vs Pre-CT), MRH (Post-CT vs Pre-CT) and MRL (Post-CT vs Pre-CT)-. B) Venn diagram outlining
differentially expressed genes after chemotherapy in each pathological response group with respect differentially expressed genes after
chemotherapy considering all experimental groups. C) Venn diagram outlining differentially expressed genes after chemotherapy in the four
pathological response groups. D) Log10 fold change in mRNA abundance of genes differentially expressed after chemotherapy considering all
experimental groups together (Post-CT vs Pre-CT) and GR –GR (Post-CT vs Pre-CT)-.
doi:10.1371/journal.pone.0053983.g002
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expression was significantly up-regulated after chemotherapy
considering all groups (Figure 1A, 1B, Table S1). Gene ontology
(GO) analysis revealed that the proteins coded by these genes were
mainly involved in extracellular matrix metabolism, cell prolifer-
ation and adhesion, oxidative stress response, angiogenesis and
developmental processes (Fig. 1C). These are key processes in
breast cancer chemoresistance and progression given their central
role in invasion and connections with cellular dedifferentiation
[2,22]. Further study of the molecular signaling pathways in which
these proteins are involved allowed the selection of 41 out of the 65
gene sequences detected and 49 additional genes of interest to test
in a validation assay (Table S2). Remarkably, validation of the
microarray results by quantitative reverse transcriptase PCR
(qRT-PCR) in an independent data set confirmed previous
observations, except for 4 out of the 41 genes selected for
validation –CDC42 binding protein kinase alpha (DMPK-like)
(CDC42BPA), protocadherin 7 (PCDH7), purine-rich element
binding protein A (PURA) and SPARC related modular calcium
binding 2 (SMOC2)-. In sum, in a cohort of 106 breast cancer
patients and 207 tumor samples we identified a set of 37 genes
significantly up-regulated after chemotherapy.
Notably, intra-group differences revealed an increasing number
of differentially over-expressed genes after chemotherapy as
pathological response to chemotherapy improved (Figure 2A, B,
C, Table S3). Post-chemotherapy vs Pre-chemotherapy compar-
ison yielded 55 differentially expressed genes in the GR group,
while the same comparison within the BR group did not identify
any differentially expressed gene after chemotherapy. Interesting-
ly, all these genes were over-expressed after chemotherapy except
two of them -adaptor-related protein complex 1, mu 2 subunit
(AP1M2) and topoisomerase (DNA) II alpha (TOP2A)- (Table S4).
These results suggest that the high proportion of chemotherapy-
induced cancer cell death observed in the GR group is
accompanied by pronounced changes in gene expression, while
a moderate effect of chemotherapy on cancer cell survival, as
noted by microscopic analysis of the pre- and post-chemotherapy
samples in the BR group, is also undetectable at the genetic level.
Comparisons between groups before and after chemotherapy
yielded interesting and clarifying results. Before chemotherapy,
GR and BR groups significantly differed in the expression of 46
sequences, all of which resulted to be repressed in the GR group
with respect the BR group (Figure 3A, Table S5). Surprisingly, we
realized that 30 of the genes composing the result list of the intra-
group comparison for GR group were also present in the
comparison GR vs BR before chemotherapy, but with shifted
expression, except for AP1M2 (Figure 3B, 3C, Table 2). In other
Figure 3. Chemoresistance gene set. A) Log10 fold change in mRNA abundance of genes differentially expressed before chemotherapy when
comparing GR and BR groups. B) Log10 fold change in mRNA abundance of genes differentially expressed for GR (Post-CT vs Pre-CT) comparison and
Pre-CT (GR vs BR) comparison C) Venn diagram outlining differentially expressed genes in GR (Post-CT vs Pre-CT) and Pre-CT (GR vs BR) comparisons.
doi:10.1371/journal.pone.0053983.g003
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words, we observed that the expression levels of 30 genes, which
significantly differed between chemo-sensitive and chemoresistant
breast tumors before chemotherapy, shifted from repression to
over-expression along chemotherapy in chemo-sensitive tumors.
The comparison between GR and BR groups after chemotherapy
showed no differences in the expression of any of the genes
analyzed, further sustaining this finding.
The comparisons concerning mid-response sub-groups
resulted in a variable number of differentially expressed genes
highlighting the molecular heterogeneity of intermediate
responses to chemotherapy (Table S6, Table S7). Nevertheless,
closer results from the comparisons involving MRH and MRL
to the results of equivalent comparisons involving GR and BR,
respectively, suggest a reliable concordance between histo-
pathological response and the expression of this set of genes
(Figure 4). With respect to Her2G, pre-chemotherapy com-
parisons confirmed the known molecular differences between
Her2-positive and Her2-negative tumors but, interestingly, the
results from post-chemotherapy comparisons involving Her2G
and post-chemotherapy vs pre-chemotherapy comparison
within the Her2G showed a higher degree of homology with
those involving GR tumors (see Supporting Discussion (Text
S1) for a detailed description).
As mentioned in the Methods section (see above), expression
data from 12 patients were excluded from final analysis due to
treatment differences. Thus, final sample size was 73 cases (146
paired pre- and post-chemotherapy samples). Nevertheless, we
performed a parallel analysis including all patients recruited
(85 cases, 170 paired pre- and post-chemotherapy samples).
Highly significant correlations between both datasets (P ,
0.001) (data not shown) highlighted the statistical robustness of
the data.
Finally, IPA analysis allowed further insights into the molecular
processes and pathways involved in breast cancer chemoresistance.
According to IPA, the 30-gene set was enriched by genes related to
cellular movement and migration, cell survival and connective
tissue development and function involving tumor cells and
fibroblasts. Additional important biological processes that were
enriched in our gene set were related to growth and proliferation
of tumor cells and fibroblasts, hematological system development
and function (mostly regarding chemotaxis and blood cells
aggregation) and cell morphology in relation to reorganization of
the cytoskeleton. Consistent with these results, the only function
close to significance which showed to be repressed is related to
organismal death (Fig. 5A). IPA network analysis generated 4
networks related to previously described functions, further
confirming the involvement of these processes in breast cancer
chemoresistance. Networks 2, 3 and 4 were interconnected,
whereas Network 1 was only related to Network 4 (Fig. 5B).
Merging overlapping networks for pathways identification resulted
in complicated models of direct and indirect interactions, so we
focused on molecular pathways associated to the highlighted
processes (see Supporting Methods (Text S1) for details).
Interestingly, despite the complexity of the network resulting from
the IPA analysis, we were able to observe that catenin (cadherin-
associated protein), beta 1 (CTNNB1), hypoxia inducible factor 1
(HIF1) and CDC42 cell division cycle 42 (CDC42) occupied
central positions in the network resulting from merging function-
ally related networks according to IPA analysis (Fig. 5C). Indeed,
after analyzing the molecular relationships between our 30 target
genes and genes known to be related with chemoresistance, cell
survival, extracellular matrix invasion and remodeling and cellular
migration we were able to observe that CTNNB1 and HIF1
continued occupying a central position within each network,
whereas the rest of target genes tended to cluster around.
Commonest canonical pathways indentified from this analysis
were the Wnt/b-catenin signaling pathway and the HIF1 signaling
pathway, together with p53 signaling pathways, Rho GTPases
signaling pathways and some other pathways related to cytoskel-
eton and tissue remodeling. Worthy of note is the presenceidenti-
fication of efficacy biomarkers for breast cancer treatment among
the genes participating in each gene expression network (Fig. 6).
Lastly, IPA analysis suggested that the expression of the 30-gene
set related to chemoresistance in our experimental system may be
promoted by 4 growth factors - Transforming growth factor beta 1
(TGF-b1), Insulin Growth Factor 1 (IGF1), Vascular Endothelial
Table 2. Genes differentially over-expressed after
chemotherapy within the GR group –GR (Post-CT vs Pre-CT)
comparison- and differentially repressed before
chemotherapy in the GR group with respect the BR group –
Pre-CT (GR vs BR) comparison.































RQ GR (Post-CT vs Pre-CT) describes the magnitude of change of each target gene
after chemotherapy with respect its expression before chemotherapy for GR
group and RQ Pre-CT (GR vs BR) describes the magnitude of change of each target
gene in the GR group with respect the BR group before chemotherapy. BR, bad
response group; GR, good response group; Post-CT, after chemotherapy; Pre-
CT, before chemotherapy; RQ, relative quantity.
doi:10.1371/journal.pone.0053983.t002
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Growth Factor A (VEGFA) and Epithelial Growth Factor (EGF)- ,
2 transcriptional factors – Myotrophin (MTPN) and Sp1
transcription factor (Sp1)- and 1 ligand-dependent nuclear
receptor - Thyroid Hormone Receptor, Beta (THRB)- (Fig. 7).
Discussion
During the last decade, many efforts have focused on the
identification of a gene signature able to either predict patient’s
prognosis or response to systemic therapies against breast cancer.
The main objective of such studies was to identify those patients
who would clearly receive a benefit from cytotoxic therapies from
those who could safely avoid this treatment [2,23]. That work
came to fruition in several commercial prognostic multigene
classifiers, whose clinical utility is being assessed in large
prospective clinical trials [24,25]. Despite initial enthusiasm, it
has been shown that the prognostic abilities of microarrays-derived
gene signatures are complementary to traditional clinicopatholog-
ical markers in clinical practice and treatment decision-making
[26]. Multigene predictors for response to chemotherapy have
been less successful, with no one of them commercially available or
being tested for clinical utility [23]. Most of these studies analyzed
tumor samples taken before chemotherapy and correlated the
resulting gene expression data with the rate of pathological
complete response (it would correspond to Miller & Payne grade 5
exclusively). Therefore the scientific novelty added by this work is
that, from the best of our knowledge, this is the first time that a
defined set of genes are reported to be expressed across breast
tumors that show different histopathological responses to chemo-
therapy. Moreover, the main objective of the present study was not
the prediction of response to chemotherapy, instead, we were
mainly interested in the discovery of genetic markers for
chemoresistance. This prompted us to include paired pre-/post-
chemotherapy samples in order to observe significant gene
expression changes selected by chemoresistant cancer cells to
cope with cytotoxicity, which is a very different approach of that
followed by preceding predictive genomic studies. Notably, this
assay was not biased for individual genetic differences, as most
samples used corresponded to paired pre- and post-treatment
samples from each case.
We have shown that a set of 30 genes, functionally related with
extracellular matrix metabolism, angiogenesis and developmental
processes, undergo a positive switch in response to anthracycline
and taxane-based chemotherapy in those patients who achieved a
good pathological response to the treatment. The magnitude of the
change reached up to a point to which transcriptional levels
became similar to those found in patients that registered a poor
histopathological response to the same treatment. These data
suggest that those cells able to overcome chemotherapy and
survive select the activation of a common transcriptional program,
Figure 4. Diagram of pre-chemotherapy and post-chemotherapy comparisons and involvement of mid-response groups. A) Log10
fold change in mRNA abundance of genes differentially expressed in common for Pre-CT (GR vs BR) and Pre-CT (GR vs MRL) comparisons. B) Venn
diagram outlining differentially expressed genes in common between Pre-CT (GR vs BR) and Pre-CT (GR vs MRL) comparisons. C) Summary of pre-CT
and post-CT comparisons.
doi:10.1371/journal.pone.0053983.g004
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regardless primary response to chemotherapy. Then, the activa-
tion of this transcriptional program may draw the underlying
molecular scenario that enable disease relapse despite chemother-
apy-derived tumor shrinkage, in both good and bad responders,
and reflect driving genetic and epigenetic aberrations which
render chemoresistance. As pointed out previously [27], breast
tumors are often composed of a mosaic of transformed cells among
which only a rare subclone may overcome chemotoxicity. In the
present study we target for analysis the cells within the residual
tumor tissue after chemotherapy, which may correspond to those
cells harboring selected genetic aberrations to resist the cytotoxic
effect of chemotherapy.
Regarding biological function, the genes selected for the
validation assay were involved in key biological processes for
breast cancer invasion, among which, extracellular matrix
metabolism, angiogenesis and developmental processes worth to
be highlighted. Recently, several works has showed the relevance
of tumor-microenvironment interactions in tumor chemoresis-
tance and clinical outcome in breast cancer [28-30]. With respect
to angiogenesis, it is well-known the involvement of this process
into breast cancer invasion and disease progression [31]. On the
other hand, some of the genes classified in the developmental
processes category have been shown to participate in molecular
pathways described in cancer stem cells (CSCs) [32-35]. Further
functional characterization was performed using IPA software.
Pathways analysis revealed that transcriptome networks, including
our target genes and genes related to chemoresistance, cell survival
and migration, and extracellular matrix remodeling and invasion,
clustered around two central genes: CTNNB1 and HIF1. b-
catenin, the protein encoded by CTNNB1, plays a key role in the
regulation of mammary development through a dual role. In
plasma membrane, b-catenin associates to cadherins forming cell-
cell adherens junctions, which maintain mammary epithelial
integrity. Loss of b-catenin from adherens junctions results in its
elevation in cytosol and nucleus, where it regulates the expression
of genes involved in mammary stem cell biology and breast
development. Importantly, both of these events have been related
to breast carcinogenesis and progression [36,37]. The nuclear
activity of b-catenin is promoted by several effectors through
different signaling pathways. Transforming Growth Factor b
(TGFb) and several Wnt proteins are known to reduce b-catenin
localization to adherens junctions by increasing the expression of
transcription factors from the ZEB, SNAIL, and TWIST protein
families and inducing the epithelial-to-mesenchymal transition
(EMT) program. The EMT is a latent embryonic process
converting epithelial cells into mesenchymal cells with enhanced
Figure 5. Functional annotation and network analysis of the Chemoresitance dataset by IPA software. A) List of predicted inhibited and
activated functions according the Chemoresistance dataset. B) Summary of the IPA network analysis of the Chemoresistance dataset C) Gene-
expression network resulting from merging overlapping Networks 2, 3 and 4 according to IPA network analysis.
doi:10.1371/journal.pone.0053983.g005
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motility and invasiveness capabilities [38]. Physiologically, EMT is
related to organogenesis but experimental evidences have shown
that the EMT process is linked to breast carcinogenesis and
progression since it promotes the acquisition of stem-like
properties, chemoresistance and metastasis [38,39]. In addition,
b-catenin localization to the nucleus is promoted by the kinase
activity of growth factors receptors, such as those of the Epidermal
Growth Factor (EGF) or the Insulin-like Growth Factor (IGF)
families, components of the Nuclear Factor kappa B (NFkB)
signaling pathway and the integrin-linked kinase (ILK) signaling
pathway, which inhibits b-catenin targeting to proteasomal
destruction [40]. Interestingly, both the ILK and the NFkB
signaling pathways have been related with the Wnt/ b-catenin
signaling pathway in our pathways analysis. Finally, increased
tumor motility conferred by EMT requires changes in cell shape
and polarity, which are mainly mediated by Rho Family GTPases
activation via Wnt/ b-catenin signaling [41], as reflected in our
pathways analysis. These facts, together with the identification of
TGFb1, IGF1 and EGF as potential upstream regulators of our 30
target genes, highlights the relevance of the molecular network
centered on b-catenin for chemoresitance in breast cancer and its
connections with the EMT process and CSCs biology, a
hypothesis that warrants further investigation.
On the other hand, the HIF family comprises several transcription
factors involved in the cellular adaptation to hypoxia through the
modulation of key processes in tumor initiation and progression, such
as angiogenesis, cell survival, metabolic reprogramming and thera-
peutic resistance. Adaptation to hypoxic conditions is crucial for tumor
development and disease progression, since oxygen deprivation is a
common microenvironmental feature of solid tumors and it increases
as tumor growths [42]. Indeed, tumor hypoxia and consequent HIF-1
overexpression have been significantly correlated with worse clinical
outcomes in cancer patients [43]. The molecular bases of these clinical
observations rely on a complex network of interactions affecting HIF-1
transcription upon physicochemical stimuli, as low oxygen tension,
increased reactive oxygen species (ROS) concentrations, growth factor
Figure 6. Gene-expression regulatory networks of breast cancer chemoresistance. Pathway analysis by IPA software based on the
Chemoresistance dataset and gene lists related to A) Chemoresistance, B) Survival, C) ECM invasion and remodeling, and D) Migration created using
the Ingenuity Knowledge Base. The relations between the genes were inferred from the relationships known in the scientific literature using data-
mining Ingenuity software. Each node represents a gene; red color denotes over-expressed genes; green color denotes down-expressed genes. The
colors intensity appears according to the related expression level by fold change. Connections indicate direct regulatory interactions. Arrows are
colored differently to ease the identification of the genes involved in over-represented Canonical Pathways and Biomarkers according to Ingenuity
Knowledge Base.
doi:10.1371/journal.pone.0053983.g006
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and cytokine signaling [42]. Recent works support the idea that cancer
chemoresistance is mediated by HIF-1-driven inactivation of intact p53
[44,45] and activation of NFkB [45]. In line with these observations,
our pathways analysis shows a connection between p53, NFkB and
HIF-1 signaling pathways in relation to chemoresistance and survival.
Regarding tumor metabolism under hypoxic conditions, it has recently
been found that Sp1 cooperates with HIF-1 to promote glycolysis in
solid tumors and thus, facilitating cancer metabolic reprogramming
and tumor progression [46]. Similarly, Thyroid hormone has been
shown to induce HIF-1a expression through THRB/Retinoid X
receptor a (RXRa)-dependent activation of the Hepatic leukemia
factor (HLF) in human hepatocytes and Hep2 cells [47], a possible role
in breast cancer metabolism according to the results of our upstream
regulator analysis with IPA software. In relation to MTPN, a protein
related to cardiac hypertrophy, no significant relation with cancer has
been reported to our knowledge. Additionally, some recent works point
out the role of HIF-1 in mediating EMT through activation of the
Wnt/b-catening signaling pathway. In 2008, Cannito et al. [48]
reported that exposure cancer cells of different epithelial origin
(hepatoma, pancreas, colon and breast carcinoma) to hypoxia
invariably resulted in EMT. Based on their in vitro experiments, the
authors proposed a mechanistic model by which early EMT events
were induced by an increase in intracellular ROS production due to
hypoxia, whereas late migration and invasiveness traits were promoted
by HIF-1 through VEGF overexpression. Later studies have
corroborated a significant enrichment in cell populations exhibiting
stem like and EMT phenotypes after exposure to hypoxia [49,50] and
very recently, Conley et al [51] have proposed that tumor hypoxia
secondary to antiangiogenic therapy in breast cancer limits its
effectiveness, as it stimulates stem-like cell enrichment through HIF1-
driven EMT.
These new data and concepts are integrated into the current debate
regarding CSCs origin and biology. The hierarchical CSCs model
proposed that oncogenesis is initiated by the occurrence of transform-
ing mutations in normal stem cells (SC), which are transferred to their
progeny following a hierarchical and unidirectional path. As a
consequence, most progenitors and differentiated tumor cells are
generated by self-renewal and differentiation of CSCs. Conceptually,
this model presents some limitations since the mutation rate of SC
might not be sufficiently high to promote oncogenesis. Main reasons
are the small size of SC population and their quiescent proliferative
state. These considerations and the biological insights coming from the
discovery and study of the EMT process in cancer have pointed out
cancer phenotypic plasticity as a major force directing oncogenesis and
tumor progression. The dedifferentiation capacity of cancer cells to a
stem-like phenotype through EMT conciliates the CSC and the multi-
step tumorigenesis models, since mutations are more likely to strike
actively dividing cells, which are later selected for clonal expansion or
Figure 7. Upstream regulators analysis by IPA software based on the Chemoresistance dataset. Each ode represents a gene; red color
denotes over-expressed genes. The colors intensity appears according to the related expression level by fold change. Connections indicate direct
regulatory interactions. Arrows are colored differently to ease the identification of each connection.
doi:10.1371/journal.pone.0053983.g007
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introduced into the CSCs compartment via EMT and upon the
appropriate stimuli. Interestingly, microenvironmental factors, such as
hypoxia, seem to trigger EMT in cancer and promote chemoresistance
[39,51].
Future studies will tell whether this set of genes for chemore-
sistance is constitutively expressed by a minority of aggressive cells
within chemo-sensitive tumors or it is up-regulated in response to
treatment-derived cytotoxicity. Similarly, further characterization
of the cells expressing this set of genes will reveal their stemness.
Indeed, they seem to share important features with undifferenti-
ated cells since they are chemoresistant, represent a minor cell
population within breast tumors, and show the up-regulation of
genes functionally related with micro-environmental signaling
pathways involved in the acquisition of motility and invasiveness
traits [34,35]. In any case, these data suggest that chemotherapy
elicits a selective pressure able to activate the expression of
adaptive capabilities in a selected population within the tumors
whose proportion may vary depending on its molecular charac-
teristics.
Then, the genes reported to differentially over-express after
chemotherapy are ideal candidates for functional analysis to test their
suitability as therapeutic targets itself or through the disruption of the
molecular pathway in which they participate. Additionally, the study of
molecular mechanism leading to the overexpression of these genes may
shed light on the genetic aberrations leading chemoresistance. On the
other hand, the development of a predictor based on the expression
levels of these genes, or a selection of them, may support treatment
decision-making in breast cancer, as it would help to identify those
patients bearing chemosensitive tumors from those whose absolute
benefit from current chemotherapy is very scarce, but still suffer from
the severe toxicity associated to the use of cytostatics and other
chemotherapeutic drugs. This strategy may allow a better selection of
candidate breast cancer patients to be included in clinical trials testing
new drugs.
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